KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $702.6 million.

  • Royalty Pharma's Cash from Operations fell 14.2% to $702.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year decrease of 1407.2%. This contributed to the annual value of $2.8 billion for FY2024, which is 732.36% down from last year.
  • As of Q3 2025, Royalty Pharma's Cash from Operations stood at $702.6 million, which was down 14.2% from $364.0 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Cash from Operations registered a high of $1.0 billion during Q1 2023, and its lowest value of $364.0 million during Q2 2025.
  • Over the past 5 years, Royalty Pharma's median Cash from Operations value was $575.0 million (recorded in 2022), while the average stood at $609.5 million.
  • Per our database at Business Quant, Royalty Pharma's Cash from Operations surged by 12461.53% in 2023 and then plummeted by 4470.08% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Cash from Operations stood at $490.0 million in 2021, then grew by 16.32% to $569.9 million in 2022, then soared by 35.57% to $772.6 million in 2023, then fell by 3.9% to $742.5 million in 2024, then dropped by 5.37% to $702.6 million in 2025.
  • Its Cash from Operations was $702.6 million in Q3 2025, compared to $364.0 million in Q2 2025 and $596.1 million in Q1 2025.